New Data Reinforce the Clinical Value of the Perceval Sutureless Valve

A study of LivaNova PLC’s Perceval sutureless valve highlights the safety, efficiency, and performance of the product, the first-ever, truly sutureless surgical valve designed for patients requiring an aortic valve replacement (AVR).
 
The study analyzed patients who underwent AVR with the Perceval bioprosthesis. The study found that AVR procedures conducted with Perceval resulted in low mortality and excellent hemodynamic performance for patients. This is the largest single center experience reported with Perceval.
 
“As one of the latest solutions in valve replacement surgery, the Perceval sutureless valve optimizes the overall surgical approach for surgeons. In the presented analysis, implantation with Perceval allowed surgeons to perform minimally invasive approaches with shorter procedure times, specifically reducing the cross-clamp and cardiopulmonary bypass time, which can lead to faster recovery times for patients,” said Dr. Marco Solinas, M.D., cardiac surgeon at G. Monasterio Tuscany Foundation in Massa, Italy.
 
The study found that Perceval, with its features, allowed surgeons to employ a minimally invasive approach during AVR procedures. At follow-up at approximately 16 months, freedom from reoperation was 99 percent and patient survival was 91.3 percent.
 
“These positive results reinforce findings from previous studies for Perceval,¹ the only truly sutureless valve designed for patients requiring surgical aortic valve replacement,” said Brian Duncan, M.D., vice president of Medical Affairs, Cardiac Surgery at LivaNova. “With the foundation of advancing technology and transforming lives, LivaNova is committed to delivering advanced solutions for cardiac surgery and we look forward to continuing the expansion of Perceval’s clinical evidence base and its growing use in the international cardiac surgery community.”
 
Perceval has been implanted in more than 20,000 patients in over 310 hospitals in 34 countries worldwide. T
 
LivaNova PLC, headquartered in London, United Kingdom, is a global medical technology company formed by the merger of Sorin S.p.A, a developer of cardiovascular disease treatments, and Cyberonics Inc., a neuromodulation specialist. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (Texas), respectively.